Join
Live feed
·
PRReleasevia Quantisnow
Terns Pharmaceuticals Inc. logo

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

ByQuantisnow·Wall Street's wire, on your screen.
TERN· Terns Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TERN (Terns Pharmaceuticals Inc.) and more on Quantisnow.